Home / ASX / Why Coles is beating Woolies post the pandemic

Why Coles is beating Woolies post the pandemic

ASX

The Coles Group Ltd (ASX: COL) share price is in focus after the supermarket business reported its FY22 half-year result.

Coles HY22 result

Coles reported several financial metrics for investors to look at:

    • Sales revenue grew 1% to $20.6 billion
    • EBITDA down 2.2% to $1.76 billion
    • EBIT down 4.4% to $975 million
    • Net profit after tax down 2% to $549 million
    • Interim dividend of $0.33 per share, 0% change

    The company was cycling strong growth in the prior year, so managing to achieve sales growth was pretty good. Over two years, supermarket sales grew by 8.6% and liquor sales were up 18.2%.

    In this result, year-on-year, supermarket sales were up 1.1% to $18 billion, liquor sales were up 2.7% and Express sales fell 8.5% to $578 million.

    Supermarket e-commerce sales grew by 46%. It has grown the number of rapid click & collect stores (order to pickup in 90 mins) to 430 as well as increasing the number of same-day home delivery stores to around 500. Liquor e-commerce sales jumped 60% – it now has four dark e-commerce stores in NSW.

    Smarter selling

    Coles said that it delivered smarter selling benefits of more than $100 million in the first half of FY22 and is on track to deliver benefits of over $200 million in FY22. This might be supportive of earnings and the Coles share price in the next couple of years.

    One strategy has been to reduce loss in-store through the use of artificial intelligence with ‘dynamic markdowns’ rolled out to the dairy category, after successful deployment in meant last year.

    Another tactic has been the alignment of meat operating models with reduced wastage and a safer working environment.

    Coles also said that there has been a service transformation in stores with the continued rollout of trolley-assisted checkouts and customer bagging benches – it gives customers more choice and helps store productivity.

    The business also pointed to e-commerce efficiency benefits with a continued focus on improved pick efficiencies and delivery van optimisation.

    It’s also providing transport solutions and other value add services to suppliers through ‘Coles Collect’ with revenue growth of 20%.

    Automated distribution centres

    Coles is working on two major automated distribution centres – one in Queensland and one in Sydney. The Witron Queensland one will be commissioned in 2023, with the Sydney one to be commissioned in FY24. The Ocado Melbourne e-commerce customer fulfilment centre is delayed to FY24.

    The supermarket business is investing significantly in its digital platforms. Coles will manage the online store and web presence for the intake of orders, whilst Ocado’s Smart Platform (OSP) will provide the automated fulfilment functionality as well as last-mile solutions.

    Fair Work Ombudsman (FWO) proceedings

    Coles is conducting a remediation program for staff that may have been underpaid. It has incurred $13 million of remediation costs with a further $12 million currently provisioned.

    FWO is investigating this and has filed proceedings in the Federal Court and alleges that Coles is obligated to pay a further $108 million for 7,687 staff for the period between 1 January 2017 to 31 March 2020.

    Coles is assessing the claims and preparing a defence.

    Outlook and my thoughts on the Coles share price

    COVID-19 has continued to cause variable impacts on Coles stores. Supermarket sales were elevated in early January, but then moderated later in the month. But Coles said that floods in South Australia have had an impact on sales, particularly in Western Australia.

    In January, it suffered $30 million of COVID costs because of the large number of COVID isolations. This has moderated in February.

    Coles has been a solid performer since the start of COVID. But I’m not sure what is the right earnings multiple valuation for Coles is with sales that are now barely moving and a rising interest rate environment. Income-focused investors may like the dividend yield, but I think there are other ASX dividend shares that could be better options.

    If you’re anything like me, you might be thinking now is a good time to have cash ‘sitting on the sidelines’.

    Information warning: The information in this article was published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169




    Print Article

    Related
    Flight Centre hits bumpy patch – but longer-term outlook smoother

    A mild warning to the market from this global travel group in October had skittish investors bailing out. Those who held their nerve could enjoy a higher payout and share price if the travel industry picks up in 2025.

    Jamie Nemtsas | 18th Dec 2024 | More
    Raiz’s quarterly numbers finally start to excite the market

    The micro fund manager reported a solid performance with increasing funds under management, revenue and active customers. On the sharemarket, investors have been finding some appetite for this stock, but it’s a far cry from the buying frenzy that took it to $2 in 2021.

    Jamie Nemtsas | 18th Dec 2024 | More
    CSL has commercial ducks lined up for a healthy 2025

    The biotech giant is poised for a strong performance, building on a solid set of numbers posted in 2024. The wildcard remains a Donald Trump presidency and the potential for disruptive economic policies.

    Jamie Nemtsas | 11th Dec 2024 | More
    Popular